Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Cash & Equivalents (2020 - 2025)

Pulse Biosciences has reported Cash & Equivalents over the past 6 years, most recently at $95.2 million for Q3 2025.

  • Quarterly results put Cash & Equivalents at $95.2 million for Q3 2025, up 20.47% from a year ago — trailing twelve months through Sep 2025 was $95.2 million (up 20.47% YoY), and the annual figure for FY2024 was $118.0 million, up 166.06%.
  • Cash & Equivalents for Q3 2025 was $95.2 million at Pulse Biosciences, down from $106.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PLSE hit a ceiling of $119.3 million in Q1 2025 and a floor of $12.7 million in Q1 2022.
  • Median Cash & Equivalents over the past 5 years was $54.1 million (2023), compared with a mean of $59.4 million.
  • Biggest five-year swings in Cash & Equivalents: soared 661.48% in 2021 and later plummeted 78.83% in 2022.
  • Pulse Biosciences' Cash & Equivalents stood at $44.4 million in 2021, then surged by 37.81% to $61.1 million in 2022, then decreased by 27.44% to $44.4 million in 2023, then surged by 166.06% to $118.0 million in 2024, then fell by 19.34% to $95.2 million in 2025.
  • The last three reported values for Cash & Equivalents were $95.2 million (Q3 2025), $106.3 million (Q2 2025), and $119.3 million (Q1 2025) per Business Quant data.